Pub Date : 2025-12-18DOI: 10.2967/jnumed.120.253443
Ian R Marsh,Harry Quon,Prasanna Santhanam,Hao Wang,Martin A Lodge,Shirley Dipasquale,Melvin Reinhardt,Dana Kaplin,Bin He,Michael Ghaly,Hanfei Qi,Paul W Ladenson,George Sgouros,Robert F Hobbs
Radiopharmaceutical therapy (RPT) of patients with differentiated metastatic thyroid cancer has been standard treatment for more than 80 y. A high and uniform expression of the NaI symporter in malignant thyroid cells results in tumoricidal absorbed doses (ADs) delivered by the β-particle emissions of the radioactive iodine (131I). Treatment is less effective for patients whose disease exhibits reduced or variable expression of NaI symporter. Methods: We have investigated a treatment strategy that combines radioiodine with external-beam radiotherapy (EBRT) for patients with low 131I uptake. By combining the AD delivered by the RPT agent with that delivered by EBRT, we achieve the targeted tumoricidal AD (80 Gy 2-Gy equieffective dose) while maintaining safe normal-organ AD. A tracer administration of RPT is used to calculate a patient-specific administered activity (AA) for therapy that yields organ-at-risk ADs below toxicity thresholds. The tumor and relevant organ-at-risk ADs from the therapeutic administration are calculated and provided to the radiation oncology medical physicists for combination therapy planning. We illustrate this precision-medicine approach to treating thyroid cancer patients using data from the first 5 patients in our ongoing clinical trial. Results: A precision-medicine approach gave an AA ranging from 14.3 to 19.5 GBq. Combined RPT-EBRT therapy of the selected lesions yielded doses ranging from 73 to 147 Gy. Conclusion: We have demonstrated the feasibility of combined RPT-EBRT in thyroid cancer patients with reduced radioiodine uptake when a standard AA of 5.55 GBq (150 mCi) would have delivered a much lower AD to lesions, less likely to lead to a response. There is considerable patient variability in clearance kinetics. Clinical benefit assessment in adjusting AA on the basis of a precision methodology would require a multicenter trial.
{"title":"Combination Radiopharmaceutical Therapy and Radiotherapy for Thyroid Cancer: Dosimetry-Driven Precision Medicine.","authors":"Ian R Marsh,Harry Quon,Prasanna Santhanam,Hao Wang,Martin A Lodge,Shirley Dipasquale,Melvin Reinhardt,Dana Kaplin,Bin He,Michael Ghaly,Hanfei Qi,Paul W Ladenson,George Sgouros,Robert F Hobbs","doi":"10.2967/jnumed.120.253443","DOIUrl":"https://doi.org/10.2967/jnumed.120.253443","url":null,"abstract":"Radiopharmaceutical therapy (RPT) of patients with differentiated metastatic thyroid cancer has been standard treatment for more than 80 y. A high and uniform expression of the NaI symporter in malignant thyroid cells results in tumoricidal absorbed doses (ADs) delivered by the β-particle emissions of the radioactive iodine (131I). Treatment is less effective for patients whose disease exhibits reduced or variable expression of NaI symporter. Methods: We have investigated a treatment strategy that combines radioiodine with external-beam radiotherapy (EBRT) for patients with low 131I uptake. By combining the AD delivered by the RPT agent with that delivered by EBRT, we achieve the targeted tumoricidal AD (80 Gy 2-Gy equieffective dose) while maintaining safe normal-organ AD. A tracer administration of RPT is used to calculate a patient-specific administered activity (AA) for therapy that yields organ-at-risk ADs below toxicity thresholds. The tumor and relevant organ-at-risk ADs from the therapeutic administration are calculated and provided to the radiation oncology medical physicists for combination therapy planning. We illustrate this precision-medicine approach to treating thyroid cancer patients using data from the first 5 patients in our ongoing clinical trial. Results: A precision-medicine approach gave an AA ranging from 14.3 to 19.5 GBq. Combined RPT-EBRT therapy of the selected lesions yielded doses ranging from 73 to 147 Gy. Conclusion: We have demonstrated the feasibility of combined RPT-EBRT in thyroid cancer patients with reduced radioiodine uptake when a standard AA of 5.55 GBq (150 mCi) would have delivered a much lower AD to lesions, less likely to lead to a response. There is considerable patient variability in clearance kinetics. Clinical benefit assessment in adjusting AA on the basis of a precision methodology would require a multicenter trial.","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"24 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145777348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-18DOI: 10.2967/jnumed.125.270910
Min Zhang,Jinyi Qian,Yingqi Jia,Shuyi Yu,Yuying Fan,Haoyu Pan,Xiaohan Wei,Zhixia Yang,Shiyan Gu,Jianzhou Wu,Tiancheng Zhou,Yue Wang,Jin Wang,Yi Chen,Jialin Teng,Chengde Yang,Biao Li,Hui Shi
Accurate assessment of vascular inflammation in large-vessel vasculitis (LVV) remains challenging, especially in patients with normal inflammatory markers or inconclusive 18F-FDG PET findings. The translocator protein 18 kDa (TSPO), a marker of inflammatory process, has emerged as a promising molecular target for imaging vascular inflammation in LVV. Methods: We prospectively enrolled 11 treatment-naïve patients with LVV and 11 healthy controls who underwent 90-min dynamic total-body 18F-DPA714 PET/CT imaging. Ten patients also underwent 18F-FDG PET/CT for direct comparison. We assessed SUVs, lesion-to-background ratios, and kinetic parameters using a 2-tissue compartment model (2T4K_vB). Peripheral blood samples from patients and controls were analyzed by flow cytometry to characterize the cellular sources of the TSPO signal. Results: 18F-DPA714 PET revealed that tracer uptake in patients with LVV was significantly higher than that in healthy controls (median SUVmean, 0.81 [interquartile range (IQR), 0.64-0.98] vs. 0.54 [IQR, 0.44-0.64]; P = 0.000-0.043). Kinetic modeling using the 2T4K_vB compartment model further confirmed the specificity of TSPO binding, demonstrating elevated parameters of irreversible binding and total distribution volume in inflamed vascular segments. In head-to-head comparisons, 18F-DPA714 showed modestly but significantly higher vessel wall-to-lumen contrast relative to 18F-FDG (lesion-to-background ratio, 1.02 [IQR, 1.00-1.15] vs. 1.00 [IQR, 0.98-1.01]; P = 0.005-0.021). Among patients with relatively lower C-reactive protein levels (<58.04 mg/L; n = 5), 18F-DPA714 detected a significantly greater inflammatory burden than did 18F-FDG (inflammatory activity burden, 3,406.4 [IQR, 1,063.6-5,624.2] vs. 0 [IQR, 0-334.8]; P = 0.043), whereas no significant intertracer difference was observed in the high C-reactive protein group (≥58.04 mg/L, n = 5). In addition, flow cytometry of peripheral blood revealed that TSPO expression was predominantly localized to monocytes and neutrophils, supporting their contribution to the PET signal in patients. Conclusion: TSPO-targeted PET imaging complements and extends current approaches to assess vascular inflammation in LVV. By enabling sensitive detection of subclinical disease, it offers a promising platform for disease monitoring.
准确评估大血管血管炎（LVV）的血管炎症仍然具有挑战性，特别是在炎症标志物正常或18F-FDG PET结果不确定的患者中。转运蛋白18kda （TSPO）是炎症过程的标志物，已成为左心室血管炎症成像的一个有希望的分子靶点。方法：我们前瞻性地招募了11名treatment-naïve LVV患者和11名健康对照者，他们接受了90分钟动态全身18F-DPA714 PET/CT成像。10例患者行18F-FDG PET/CT直接比较。我们使用2组织室模型（2T4K_vB）评估suv、病变与背景比和动力学参数。通过流式细胞术分析患者和对照组的外周血样本，以表征TSPO信号的细胞来源。结果：18F-DPA714 PET显示，LVV患者的示踪剂摄取显著高于健康对照组(中位SUVmean， 0.81[四分位数间距（IQR）， 0.64-0.98] vs. 0.54 [IQR, 0.44-0.64]；P = 0.000-0.043)。2T4K_vB室模型的动力学建模进一步证实了TSPO结合的特异性，显示炎症血管段的不可逆结合参数和总分布体积升高。在头对头比较中，18F-DPA714相对于18F-FDG表现出适度但显著的血管壁/腔对比度（病变与背景比，1.02 [IQR, 1.00-1.15] vs. 1.00 [IQR, 0.98-1.01]; P = 0.005-0.021）。在c -反应蛋白水平相对较低（<58.04 mg/L, n = 5）的患者中，18F-DPA714检测到的炎症负担明显高于18F-FDG（炎症活动性负担，3,406.4 [IQR, 1,063.6-5,624.2]比0 [IQR， 0-334.8], P = 0.043），而在高c -反应蛋白组（≥58.04 mg/L, n = 5）中未观察到明显的示间剂差异。此外，外周血流式细胞术显示，TSPO的表达主要局限于单核细胞和中性粒细胞，支持它们对患者PET信号的贡献。结论：tspo靶向PET成像补充和扩展了当前评估左室血管炎症的方法。通过实现亚临床疾病的敏感检测，它为疾病监测提供了一个有前途的平台。
{"title":"Translocator Protein 18 kDa-Targeted Total-Body PET Imaging Reveals Immune-Specific Vascular Inflammation in Large-Vessel Vasculitis: A Prospective Head-to-Head Comparison with 18F-FDG.","authors":"Min Zhang,Jinyi Qian,Yingqi Jia,Shuyi Yu,Yuying Fan,Haoyu Pan,Xiaohan Wei,Zhixia Yang,Shiyan Gu,Jianzhou Wu,Tiancheng Zhou,Yue Wang,Jin Wang,Yi Chen,Jialin Teng,Chengde Yang,Biao Li,Hui Shi","doi":"10.2967/jnumed.125.270910","DOIUrl":"https://doi.org/10.2967/jnumed.125.270910","url":null,"abstract":"Accurate assessment of vascular inflammation in large-vessel vasculitis (LVV) remains challenging, especially in patients with normal inflammatory markers or inconclusive 18F-FDG PET findings. The translocator protein 18 kDa (TSPO), a marker of inflammatory process, has emerged as a promising molecular target for imaging vascular inflammation in LVV. Methods: We prospectively enrolled 11 treatment-naïve patients with LVV and 11 healthy controls who underwent 90-min dynamic total-body 18F-DPA714 PET/CT imaging. Ten patients also underwent 18F-FDG PET/CT for direct comparison. We assessed SUVs, lesion-to-background ratios, and kinetic parameters using a 2-tissue compartment model (2T4K_vB). Peripheral blood samples from patients and controls were analyzed by flow cytometry to characterize the cellular sources of the TSPO signal. Results: 18F-DPA714 PET revealed that tracer uptake in patients with LVV was significantly higher than that in healthy controls (median SUVmean, 0.81 [interquartile range (IQR), 0.64-0.98] vs. 0.54 [IQR, 0.44-0.64]; P = 0.000-0.043). Kinetic modeling using the 2T4K_vB compartment model further confirmed the specificity of TSPO binding, demonstrating elevated parameters of irreversible binding and total distribution volume in inflamed vascular segments. In head-to-head comparisons, 18F-DPA714 showed modestly but significantly higher vessel wall-to-lumen contrast relative to 18F-FDG (lesion-to-background ratio, 1.02 [IQR, 1.00-1.15] vs. 1.00 [IQR, 0.98-1.01]; P = 0.005-0.021). Among patients with relatively lower C-reactive protein levels (<58.04 mg/L; n = 5), 18F-DPA714 detected a significantly greater inflammatory burden than did 18F-FDG (inflammatory activity burden, 3,406.4 [IQR, 1,063.6-5,624.2] vs. 0 [IQR, 0-334.8]; P = 0.043), whereas no significant intertracer difference was observed in the high C-reactive protein group (≥58.04 mg/L, n = 5). In addition, flow cytometry of peripheral blood revealed that TSPO expression was predominantly localized to monocytes and neutrophils, supporting their contribution to the PET signal in patients. Conclusion: TSPO-targeted PET imaging complements and extends current approaches to assess vascular inflammation in LVV. By enabling sensitive detection of subclinical disease, it offers a promising platform for disease monitoring.","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145777347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-18DOI: 10.2967/jnumed.125.270683
Farzana Z Ali,Pawan K Gupta,Martin S Allen-Auerbach
{"title":"Beyond the Prostate: Incidental Detection of Male Breast Carcinoma on [18F]DCFPyl.","authors":"Farzana Z Ali,Pawan K Gupta,Martin S Allen-Auerbach","doi":"10.2967/jnumed.125.270683","DOIUrl":"https://doi.org/10.2967/jnumed.125.270683","url":null,"abstract":"","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145777346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-11DOI: 10.2967/jnumed.125.271364
James R Bading,Joanne E Mortimer
{"title":"The Role of HER2 PET in Treatment of Breast Cancer.","authors":"James R Bading,Joanne E Mortimer","doi":"10.2967/jnumed.125.271364","DOIUrl":"https://doi.org/10.2967/jnumed.125.271364","url":null,"abstract":"","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145728564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-11DOI: 10.2967/jnumed.125.271248
Anita Brink,Janke Kleynhans,Anna Grigoryan,Walid Omar,Bethlehem W Mekonnen,Olumayowa U Kolade,Kgomotso Mokoala,Bright A Sangiwa,Francis Hashford,Harish Nagaraj,Tamer M Sakr,Naoual Bentaleb,Francesco Giammarile,Enrique Estrada-Lobato,Amal Elrefaei,Peter Knoll,Aruna Korde,Diana Paez
We aimed to investigate the current status of nuclear medicine (NM) services across Africa, including identifying infrastructure gaps, radiopharmaceutical availability, systemic challenges, uneven growth trends, and efforts to improve access. Methods: Data on NM infrastructure, radiopharmaceutical availability, and challenges faced by NM professionals in the region were collected at regional International Atomic Energy Agency (IAEA) training courses, from IAEA databases, and by direct correspondence with NM professionals in the region between September 2024 and September 2025. Results: NM services are available in 29 countries. Seven countries have more than 1 SPECT or SPECT/CT camera per million inhabitants, and 12 countries offer PET/CT services, with no country in the region having more than 1 PET/CT camera per million inhabitants. There are 29 cyclotrons in 11 countries. There has been a 5.58% compound annual growth rate of SPECT or SPECT/CT and 32.8% growth (above global averages) in PET/CT cameras since 2022. 99mTc is available in all countries with NM services, and all, except Burkina Faso, have access to 131I. Prostate-specific membrane antigen imaging is available in 9 countries, and somatostatin receptor type 2 imaging is available in 8 countries. Targeted radiopharmaceutical therapy services are limited to 131I for benign or malignant thyroid disease in most countries. 177Lu-therapies are restricted to 7 countries, and the availability of [131I]MIBG remains limited. Clinical trials with 225Ac and 161Tb are under way. Member states face similar challenges, including high costs of medical equipment and consumables, limited health care infrastructure, low government health care expenditures, weak economies, staff shortages, and limited educational opportunities. Conclusion: Despite challenges, there is clear momentum and NM growth in Africa. Although infrastructure, radiopharmaceutical access, and workforce gaps remain, data show progress. Sustained investment in facilities, training, and regulatory frameworks is essential to achieve equitable access to care. IAEA's regional anchor centers as part of the Rays of Hope initiative exemplifies strategic capacity building, collaboration, and knowledge sharing in the region.
{"title":"The Current Status of Nuclear Medicine in Africa.","authors":"Anita Brink,Janke Kleynhans,Anna Grigoryan,Walid Omar,Bethlehem W Mekonnen,Olumayowa U Kolade,Kgomotso Mokoala,Bright A Sangiwa,Francis Hashford,Harish Nagaraj,Tamer M Sakr,Naoual Bentaleb,Francesco Giammarile,Enrique Estrada-Lobato,Amal Elrefaei,Peter Knoll,Aruna Korde,Diana Paez","doi":"10.2967/jnumed.125.271248","DOIUrl":"https://doi.org/10.2967/jnumed.125.271248","url":null,"abstract":"We aimed to investigate the current status of nuclear medicine (NM) services across Africa, including identifying infrastructure gaps, radiopharmaceutical availability, systemic challenges, uneven growth trends, and efforts to improve access. Methods: Data on NM infrastructure, radiopharmaceutical availability, and challenges faced by NM professionals in the region were collected at regional International Atomic Energy Agency (IAEA) training courses, from IAEA databases, and by direct correspondence with NM professionals in the region between September 2024 and September 2025. Results: NM services are available in 29 countries. Seven countries have more than 1 SPECT or SPECT/CT camera per million inhabitants, and 12 countries offer PET/CT services, with no country in the region having more than 1 PET/CT camera per million inhabitants. There are 29 cyclotrons in 11 countries. There has been a 5.58% compound annual growth rate of SPECT or SPECT/CT and 32.8% growth (above global averages) in PET/CT cameras since 2022. 99mTc is available in all countries with NM services, and all, except Burkina Faso, have access to 131I. Prostate-specific membrane antigen imaging is available in 9 countries, and somatostatin receptor type 2 imaging is available in 8 countries. Targeted radiopharmaceutical therapy services are limited to 131I for benign or malignant thyroid disease in most countries. 177Lu-therapies are restricted to 7 countries, and the availability of [131I]MIBG remains limited. Clinical trials with 225Ac and 161Tb are under way. Member states face similar challenges, including high costs of medical equipment and consumables, limited health care infrastructure, low government health care expenditures, weak economies, staff shortages, and limited educational opportunities. Conclusion: Despite challenges, there is clear momentum and NM growth in Africa. Although infrastructure, radiopharmaceutical access, and workforce gaps remain, data show progress. Sustained investment in facilities, training, and regulatory frameworks is essential to achieve equitable access to care. IAEA's regional anchor centers as part of the Rays of Hope initiative exemplifies strategic capacity building, collaboration, and knowledge sharing in the region.","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145728561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-11DOI: 10.2967/jnumed.125.271103
Laura Schäfer,Betül Altunay,Agnieszka Morgenroth,Andreas Vogg,Yvonne Derks,Twan Lammers,Quim Peña,Felix Manuel Mottaghy,Susanne Lütje
Molecularly targeted therapies are increasingly relevant in clinical oncology, as they enable the selective modulation of specific biologic targets-such as enzymes or receptors-by inhibiting or enhancing their function. Nectin cell adhesion molecule 4 (nectin-4), a tumor-associated antigen, is overexpressed in various malignancies and has been linked to tumor progression and poor clinical outcomes. Its role has recently gained significant attention, particularly in urothelial carcinoma, where nectin-4-targeted antibody-drug conjugates have demonstrated promising therapeutic efficacy. These findings have positioned nectin-4 not only as a relevant target for noninvasive tumor characterization and cancer therapy but also as a valuable biomarker for molecular imaging. This review provides an overview of the recent developments in nectin-4-directed molecular theranostics, on the basis of a literature analysis, with a focus on the design, preclinical validation, and clinical translation of novel radiotracers in nuclear medicine. Multiple nectin-4-targeted radiotracers-comprising antibody- and peptide-based agents-have demonstrated high specificity and strong affinity for nectin-4-overexpressing tumors, particularly in urothelial carcinoma and triple-negative breast cancer. Exploratory preclinical and clinical data consistently showed comparable diagnostic accuracy to standard molecular imaging methods (e.g., [18F]FDG-based PET), enhanced detection of metastatic lesions, and effective monitoring of therapeutic response and eventual treatment resistance to nectin-4-targeted antibody-drug conjugates.
{"title":"Nectin-4-Targeted Radiotheranostics for Personalized Cancer Therapy: A Systematic Review.","authors":"Laura Schäfer,Betül Altunay,Agnieszka Morgenroth,Andreas Vogg,Yvonne Derks,Twan Lammers,Quim Peña,Felix Manuel Mottaghy,Susanne Lütje","doi":"10.2967/jnumed.125.271103","DOIUrl":"https://doi.org/10.2967/jnumed.125.271103","url":null,"abstract":"Molecularly targeted therapies are increasingly relevant in clinical oncology, as they enable the selective modulation of specific biologic targets-such as enzymes or receptors-by inhibiting or enhancing their function. Nectin cell adhesion molecule 4 (nectin-4), a tumor-associated antigen, is overexpressed in various malignancies and has been linked to tumor progression and poor clinical outcomes. Its role has recently gained significant attention, particularly in urothelial carcinoma, where nectin-4-targeted antibody-drug conjugates have demonstrated promising therapeutic efficacy. These findings have positioned nectin-4 not only as a relevant target for noninvasive tumor characterization and cancer therapy but also as a valuable biomarker for molecular imaging. This review provides an overview of the recent developments in nectin-4-directed molecular theranostics, on the basis of a literature analysis, with a focus on the design, preclinical validation, and clinical translation of novel radiotracers in nuclear medicine. Multiple nectin-4-targeted radiotracers-comprising antibody- and peptide-based agents-have demonstrated high specificity and strong affinity for nectin-4-overexpressing tumors, particularly in urothelial carcinoma and triple-negative breast cancer. Exploratory preclinical and clinical data consistently showed comparable diagnostic accuracy to standard molecular imaging methods (e.g., [18F]FDG-based PET), enhanced detection of metastatic lesions, and effective monitoring of therapeutic response and eventual treatment resistance to nectin-4-targeted antibody-drug conjugates.","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"249 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145728480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-11DOI: 10.2967/jnumed.125.271241
Randy Yeh
{"title":"Reply: The Role of HER2 PET in Treatment of Breast Cancer.","authors":"Randy Yeh","doi":"10.2967/jnumed.125.271241","DOIUrl":"https://doi.org/10.2967/jnumed.125.271241","url":null,"abstract":"","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"26 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145728476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Molecular imaging is redefining in vivo characterization of multiple sclerosis, a demyelinating disease with complex and heterogeneous clinical profiles. Recent advances in PET tracers enable more specific detection of pathologic features beyond conventional MRI. Among them, [18F]3F4AP-a fluorinated analog of 4-aminopyridine-targets voltage-gated potassium channels that become exposed after demyelination, offering a promising tool to detect myelin loss. Similarly, [11C]PiB and [11C]MeDAS, originally developed for amyloid and myelin imaging, respectively, exhibit high affinity for myelin, allowing direct assessment of white matter integrity. In particular, [11C]MeDAS shows selective binding to intact myelin sheaths and strong correlation with histologic myelin content in preclinical models. These agents have demonstrated utility in both animal studies and early clinical investigations, supporting their translational relevance. This review focuses on the pharmacologic properties, imaging protocols, and developmental progress of PET tracers that directly or indirectly reflect demyelination, advancing personalized approaches to diagnosis, monitoring, and therapeutic evaluation in multiple sclerosis.
{"title":"Illuminating Multiple Sclerosis: Next-Generation PET Tracers for Molecular Insights.","authors":"Luca Urso,Alessandra Boschi,Orazio Schillaci,Luca Filippi,Licia Uccelli","doi":"10.2967/jnumed.125.271204","DOIUrl":"https://doi.org/10.2967/jnumed.125.271204","url":null,"abstract":"Molecular imaging is redefining in vivo characterization of multiple sclerosis, a demyelinating disease with complex and heterogeneous clinical profiles. Recent advances in PET tracers enable more specific detection of pathologic features beyond conventional MRI. Among them, [18F]3F4AP-a fluorinated analog of 4-aminopyridine-targets voltage-gated potassium channels that become exposed after demyelination, offering a promising tool to detect myelin loss. Similarly, [11C]PiB and [11C]MeDAS, originally developed for amyloid and myelin imaging, respectively, exhibit high affinity for myelin, allowing direct assessment of white matter integrity. In particular, [11C]MeDAS shows selective binding to intact myelin sheaths and strong correlation with histologic myelin content in preclinical models. These agents have demonstrated utility in both animal studies and early clinical investigations, supporting their translational relevance. This review focuses on the pharmacologic properties, imaging protocols, and developmental progress of PET tracers that directly or indirectly reflect demyelination, advancing personalized approaches to diagnosis, monitoring, and therapeutic evaluation in multiple sclerosis.","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145728481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-11DOI: 10.2967/jnumed.125.271101
Jiaming Song,Jiani Ye
{"title":"Critical Evaluation of HER2 PET Imaging in Metastatic Breast Cancer: Addressing Key Challenges and Future Directions.","authors":"Jiaming Song,Jiani Ye","doi":"10.2967/jnumed.125.271101","DOIUrl":"https://doi.org/10.2967/jnumed.125.271101","url":null,"abstract":"","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145728565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-11DOI: 10.2967/jnumed.125.271194
Sara Lopes van den Broek, Klas Bratteby, Ximena Aguilar, Thuy A. Tran, Stina Syvänen, Dag Sehlin
Visual Abstract
视觉文摘
{"title":"Radionuclide Selection Influences Imaging Outcomes in Immuno-PET with a Brain-Penetrating Anti–Amyloid-β Antibody","authors":"Sara Lopes van den Broek, Klas Bratteby, Ximena Aguilar, Thuy A. Tran, Stina Syvänen, Dag Sehlin","doi":"10.2967/jnumed.125.271194","DOIUrl":"https://doi.org/10.2967/jnumed.125.271194","url":null,"abstract":"<sec><st>Visual Abstract</st><p><fig loc=\"float\"><link locator=\"jnumed.125.271194absf1\"></fig></p></sec>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"366 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145728871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：